Peripheral Lung Cancer - Pipeline Insights, 2016


#566515

80pages

DelveInsight

$ 1450

In Stock

DelveInsight

Table of Content:

Peripheral Lung Cancer Overview
Types
Peripheral Lung Cancer (Lung adenocarcinoma)
Epidemiology
Diagnosis of adenocarcinoma
Treatment of Adenocarcinoma of the lung
Pipeline Therapeutics
Therapeutics under Development by Companies
Last Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Discovery and Pre-clinical Stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Dormant Products
Companies involved in Therapeutics Development

Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer

Table 1: Number of Products Under Development for Peripheral Lung Cancer, 2016
Table 2: Number of Products under Development by Companies,2016
Table 3: Last Stage Products (Phase III and Filed),2016
Table 4: Mid Stage Products (Phase II), 2016
Table 5: Early Stage Products (Phase I and IND), 2016
Table 6: Discovery and Pre-clinical Stage Products, 2016
Table 7: Assessment by Monotherapy Products, 2016
Table 8: Assessment by Route Of Administration, 2016
Table 9: Assessment by Stage and Route Of Administration, 2016
Table 10: Assessment by Molecule Type, 2016
Table 11: Assessment by Stage and Molecule Type, 2016
Table 12: Dormant Drugs, 2016
Table 13: Companies Involved in Therapeutic Development, 2016

Figure 1: Number of Products under Development for Peripheral Lung Cancer, 2016
Figure 2: Last Stage Products (Phase III) 2016
Figure 3: Mid Stage Products (Phase II), 2016
Figure 4:Early Stage Products (Phase I and IND), 2016
Figure 5: Discovery and Pre-clinical Stage Products, 2016
Figure 6: Assessment by Monotherapy Products, 2016
Figure 7: Assessment by Route of Administration, 2016
Figure 8: Assessment by Stage and Route of Administration, 2016
Figure 9: Assessment by Molecule Type, 2016
Figure 10: Assessment by Stage and Molecule Type, 2016